CN101732420A - Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases - Google Patents
Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases Download PDFInfo
- Publication number
- CN101732420A CN101732420A CN200810177501A CN200810177501A CN101732420A CN 101732420 A CN101732420 A CN 101732420A CN 200810177501 A CN200810177501 A CN 200810177501A CN 200810177501 A CN200810177501 A CN 200810177501A CN 101732420 A CN101732420 A CN 101732420A
- Authority
- CN
- China
- Prior art keywords
- daphniphyllum calycinum
- group
- present
- herba polygoni
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of a daphniphyllum calycinum benth and red-knees herb composition in preparing a medicament for preventing and treating rheumatic diseases. The invention is characterized in that during preparing the medicament for preventing and treating the rheumatic diseases, an adopted effective constituent is prepared from the following traditional Chinese medicine raw materials in parts by weight: 1-9 parts of daphniphyllum calycinum benth and 1-9 parts of red-knees herb. The medicament prepared by the application has definite curative effect for preventing and treating the rheumatic diseases, durable action and no obvious side effect and better solves the problems of treatment drugs and prevention drugs for the rheumatic diseases.
Description
Technical field
The invention belongs to a kind of application of Chinese medicine pharmaceutical composition, particularly prevent and treat the application of rheumatism medicine as preparation.
Background technology
Traditional medicine thinks that arthromyodynia is that making QI and blood meridian is that the pathogenic factor impatency causes because the human body the four stages in the course of an epidemic febrile disease is lacked of proper care, and flesh table and meridians suffer the damp and hot invasion and attack of wind and cold.The patient be usually expressed as the pain of passages through which vital energy circulates, skin, joint and muscles and bones, miserable numbness, emphatically, joint stuffiness or arthroncus, stiff, lopsided, amyotrophy, moving obstacle, severe patient can influence internal organs.The rheumatism of modern medicine is similar to arthromyodynia on the Chinese medicine.Primary disease is commonly encountered diseases, frequently-occurring disease, does not still have the specific treatment method at present.
Summary of the invention
The technical problem to be solved in the present invention provides the application as preparation control rheumatism medicine of a kind of Daphniphyllum calycinum and Herba polygoni hydropiperis compositions, and the medicine that this applications prepares has the advantage that curative effect is obvious, toxic and side effects is little.
The technical scheme that addresses the above problem is that when preparing the medicine of preventing and treating rheumatism with the present invention, the effective ingredient of employing is made up of the following weight Chinese medicinal raw materials:
Daphniphyllum calycinum 1-9 part Herba polygoni hydropiperis 1-9 part.
Preferred version is that the effective ingredient of employing is made up of the following weight Chinese medicinal raw materials:
Daphniphyllum calycinum 1-6 part Herba polygoni hydropiperis 1-6 part.
Further preferred version is that the effective ingredient of employing is made up of the following weight Chinese medicinal raw materials again:
1 part of 2 parts of Herba polygoni hydropiperis of Daphniphyllum calycinum.
The pharmaceutical composition of above-mentioned application preparation can be the dosage form on all pharmaceuticss such as tablet, granule, capsule, pill, drop pill, soft capsule.
The rheumatism of described pharmaceutical composition control belongs to traditional Chinese medical science arthromyodynia one class, can be the disease that rheumatoid arthritis, rheumatic arthritis, ankylosing spondylitis, osteoarthritis, gout, systemic lupus erythematosus (sle), systemic sclerosis, polymyositis and dermatomyositis, sjogren syndrome, psoriatic arthritis etc. influence bone, joint and surrounding soft tissue.
The existing clinically 'Fengliaochangweikang' ' sheet treatment of forming by a certain percentage with Daphniphyllum calycinum and Herba polygoni hydropiperis is strong by middle fortune, wet acute gastroenteritis and the indigestions such as caused abdominal distention, stomachache and diarrhoea thereof due to tired of the stagnation of QI.But there is no report both at home and abroad by the pharmaceutical composition control rheumatism that Daphniphyllum calycinum and Herba polygoni hydropiperis are formed.
The traditional Chinese medical science is often with control rheumatism such as the removing dampness of dispeling the wind, dispelling cold by warming the meridian or heat clearing away collateral dredging.The present invention finds, can obtain obvious curative effects with Daphniphyllum calycinum and Herba polygoni hydropiperis control rheumatism.Its mechanism is: Daphniphyllum calycinum has heat-clearing and toxic substances removing, relaxing muscles and tendons to promote blood circulation effect, the treatment rheumatalgia that the traditional Chinese medical science is used always, cold, fever, tonsillitis etc.; The Herba polygoni hydropiperis dehumidifying of detoxifying, the dissipating blood stasis hemostasis cures mainly rheumatalgia, has loose bowels, carbuncle, eczema, metrorrhagia etc.; The hot temperature of Herba polygoni hydropiperis, Daphniphyllum calycinum is bitter cool, the two compatibility, the bitter cool and usefulness of hot temperature, have removing damp-heat, regulate the flow of vital energy be good for the stomach, cooperative effect such as promoting qi circulation, resolving food retention.
It is definite that the present invention uses the curative effect of medication of control rheumatism of preparation, and effect is lasting, and non-evident effect has solved the problem of rheumatism medicine for treatment and prophylactic preferably.
The specific embodiment
Embodiment 1
This example is got Daphniphyllum calycinum 4000g, and Herba polygoni hydropiperis 2000g adds 6 times of water gagings and soaks after 2 hours, decoct and extract 2 times, the 1st time 1.5 hours, the 2nd time 1 hour, collecting decoction filters, and filtrate decompression is concentrated into thick paste, drying obtains dried medicated powder, is ground into fine powder, add appropriate amount of starch etc., mixing is made granule, be pressed into 1000, sugar coating, tablet.
Be the zoopery situation that this example is used the preparation medicine below:
With the dried medicated powder of complex group that obtains through steps such as decoctings in the above-mentioned manufacturing process; And obtain single respectively by steps such as decoctings with group Daphniphyllum calycinum extract and single with the dried medicated powder of group Herba polygoni hydropiperis extract.More than three kinds of dried medicated powder of the every gram of extract all be equivalent to crude drug 25g.Face with preceding and arabic gum mixed grinding, be mixed with desired concn (containing 5% arabic gum) with distilled water.
1, to the preventive and therapeutic effect of rat assist agent arthritis
SD is 40 of rats, and body weight 140-160g is male, is divided into model control group at random, and the Daphniphyllum calycinum list is used and organized cortisone matched group, complex group of the present invention, 8 every group with group, Herba polygoni hydropiperis list.Under etherization, with Freund's complete adjuvant 0.05ml (include fast knot nuclear bacillus 0.5mg) intradermal injection in every right back foot pad of rat, beginning administration in the 8th day behind the injection adjuvant, be administered once every day, of the present invention group of per kilogram filling every day stomach gives 2g of the present invention (crude drug) (down together), Daphniphyllum calycinum group per kilogram every day is irritated stomach and is given Daphniphyllum calycinum extract 2g, Herba polygoni hydropiperis group per kilogram every day is irritated stomach and is given Herba polygoni hydropiperis extract 2g, cortisone group per kilogram every day intramuscular injection cortisone 25mg, model control group is irritated stomach and is given equal volume solvent (i.e. 5% arabic gum) (same down), shared medicine to the injection adjuvant the 21st day.Continue after the drug withdrawal to observe 3 days, killed rat, and took by weighing thymus, spleen and adrenal gland in the 24th day.Injection adjuvant before and after 3 hours and afterwards every 3 days each survey about sufficient sole of the foot volume 1 time, the difference of volume is the swelling degree before and after the adjuvant in giving with the parapodum sole of the foot.Observe rat ear erythema simultaneously, situation appears in afterbody tuberosity etc.Weighed once every 3 days in addition.
The result shows, after of the present invention group of therapeutic used, can not only obviously suppress early stage inflammatory reaction of the injection adjuvant parapodum sole of the foot and later stage swelling once again, and the parapodum sole of the foot Secondary cases swelling in addition of injection adjuvant is not also had obvious inhibitory action, and action intensity and cortisone are close.In the whole experiment, no matter be the present invention, or cortisone, there is no obvious minimizing animal ingestion amount and body weight, rat ear erythema and afterbody lesser tubercle etc. are all than the obvious minimizing of model control group.In addition, do not find that the present invention has a significant effect to rat chest gland, spleen and adrenal gland's index.No matter be Daphniphyllum calycinum list group, or Herba polygoni hydropiperis list group, though certain antiinflammatory action is arranged, all than a little less than the present invention, Daphniphyllum calycinum and Herba polygoni hydropiperis can produce obvious collaborative antiphlogistic effects among prompting the present invention behind the science compatibility.
2, the inhibitory action of rat paw edema due to the on Carrageenan
SD is 50 of rats, male, body weight 140-180g, be divided into dosage group (irritate stomach and give 1.0g/kg of the present invention) among model control group (irritate stomach and give the equal-volume solvent), prednisone matched group (lumbar injection prednisone 5mg/kg), small dose group of the present invention (irritate stomach and give 0.5g/kg of the present invention), the present invention at random, the heavy dose of group of the present invention (irritate stomach and give 2.0g/kg of the present invention), 10 every group.Half an hour after the administration, inject 1% carrageenin 0.1ml down in the right back sufficient plantar aponeurosis of rat.Measured the foot swelling value behind the Yu Zhiyan in 1,2,4,6 hour respectively.
The result shows, causing scorching back 1 hour model control group swelling value is 0.125 ± 0.012ml, small dose group swelling value of the present invention is 0.062 ± 0.025ml, middle dosage group is 0.046 ± 0.019ml, heavy dose of group is 0.024 ± 0.011ml, and the prednisone group is 0.042 ± 0.020ml, points out antiinflammatory action of the present invention obvious, middle dosage can reach the effect suitable with prednisone, and onset is rapid.Cause scorching back 6 hours and measure the rat paw edema value, and calculate the swelling rate, the result, model control group swelling rate is 65.8%, the prednisone group is 34.5%, the present invention is little, in, heavy dose of group is respectively 48.2%, 29.5% and 19.8%, further point out the present invention not only the rat paw edema that causes of on Carrageenan the obvious suppression effect is arranged, and dose-effect relationship is very obvious.
3, the antagonism of rat paw edema due to the PARA FORMALDEHYDE PRILLS(91,95)
SD is a rat, and is male, and body weight 140-160g is divided into 5 groups at random, 8 every group, half an hour after the administration, injects 2.5% formaldehyde 0.1ml in the right back sufficient sole of the foot of rat and causes inflammation.The present invention is little, in, heavy dose of group irritates stomach respectively and gives 0.5g/kg of the present invention, 1.0g/kg and 2.0g/kg, prednisone group lumbar injection prednisone 5mg/kg, model control group is irritated stomach and is given isopyknic solvent.Measured the rat paw edema value behind the Yu Zhiyan in 2,4,6,24,48,72 and 96 hours respectively.The result, the present invention is in causing scorching back 2 hours i.e. antiinflammatory actions, model group pedal swelling value is 0.656 ± 0.162ml, the present invention is little, in, heavy dose of group is respectively 0.487 ± 0.143,0.392 ± 0.121,0.283 ± 0.105ml, the prednisone group is 0.375 ± 0.162ml, and dosage has reached the antiphlogistic effects similar to prednisone among visible the present invention.Further observe and find, the antagonism of PARA FORMALDEHYDE PRILLS(91,95) swelling of the present invention can last till always and causes scorching back 96 hours.Causing scorching back 96 hours model group pedal swelling values is 0.447 ± 0.098ml, the prednisone group is 0.356 ± 0.082ml, small dose group of the present invention is 0.345 ± 0.061ml, middle dosage group is 0.302 ± 0.072ml, heavy dose of group is 0.263 ± 0.113ml, credit is analysed by statistics, prednisone group and small dose group of the present invention and model control group are relatively, all no longer include tangible antiinflammatory action, but among the present invention, heavy dose of group and model control group relatively, still more obvious to the antagonism of rat formaldehyde foot swelling.
4, to the inhibitory action of mouse skin delayed hypersensitivity
Getting ICR is 70 of mices, the male and female dual-purpose, body weight 18-22g, be divided at random model control group, prednisone matched group, Daphniphyllum calycinum list little with group, Herba polygoni hydropiperis list with group, the present invention, in, heavy dose of group, 10 every group.The grouping back is with 5%2,4 one dinitrochlorobenzene alcoholic solution are coated mouse part skin sensitization, sensitization beginning in preceding 1 day administration, every day 1 time, continuous 9 days, sensitization was coated with auris dextra with 1%2,4 one dinitrochlorobenzene (being dissolved in the olive oil) after 7 days and attacks, put to death mice after 24 hours, with the heavy difference of left and right sides ear as the delayed hypersensitivity value.The results are shown in following table:
Table 1, the present invention are to the inhibitory action of 2,4 one dinitrochlorobenzene induced mice skin delayed hypersensitivitys
| Group | Dosage (g/kg) | Route of administration | Number of animals (only) | Two ear method of double differences values (mean ± standard deviation) |
| The model contrast | ??- | Irritate stomach | ??10 | ??7.85±2.14 |
| Prednisone | ??0.025 | Lumbar injection | ??10 | ??1.92±0.52*** |
| The present invention | ??0.5 | Irritate stomach | ??10 | ??3.47±1.28** |
| The present invention | ??1.0 | Irritate stomach | ??10 | ??2.63±1.07** |
| The present invention | ??2.0 | Irritate stomach | ??10 | ??2.15±0.72*** |
| The Daphniphyllum calycinum list is used | ??2.0 | Irritate stomach | ??10 | ??6.12±1.34* |
| The Herba polygoni hydropiperis list is used | ??2.0 | Irritate stomach | ??10 | ??5.29±1.25* |
Compare * p＜0.05, * * p＜0.01, * * * p＜0.001 with model control group.
The result shows that the medicine that the present invention uses preparation has obvious inhibitory action to the mouse skin delayed hypersensitivity, and effect obviously is better than Daphniphyllum calycinum or Herba polygoni hydropiperis list usefulness, and presents a certain amount of effect relationship.The heavy dose of group of the present invention can reach the effect close with prednisone.
5, to the inhibitory action of mice reticuloendothelial system phagocytic function
ICR is a mice, body weight 18-22g, and the male and female dual-purpose is divided into 7 groups by table 2,10 every group.Experimentize by Boiggi india ink method.The difference successive administration is 5 days after the mice group, and every day 1 time, the mice phagocytic function is measured in the last administration after 24 hours.The results are shown in Table 2.The result shows, among the present invention, when heavy dose of mice reticuloendothelial system phagocytic function is had inhibitory action, but a little less than than prednisone being, low dose of and Daphniphyllum calycinum list usefulness of the present invention or Herba polygoni hydropiperis list are used the inhibitory action of phagocytic function all not obvious.
Table 2 the present invention is to the inhibitory action of mice reticuloendothelial system phagocytic function
| Group | Dosage (g/kg) | Route of administration | Phagocytic function (K value) (mean ± standard deviation) |
| The solvent contrast | ??- | Irritate stomach | ??0.048±0.012 |
| Prednisone | ??0.005 | Intramuscular injection | ??0.021±0.007*** |
| The present invention | ??0.5 | Irritate stomach | ??0.045±0.014 |
| The present invention | ??1.0 | Irritate stomach | ??0.035±0.017* |
| The present invention | ??2.0 | Irritate stomach | ??0.032±0.011* |
| The Daphniphyllum calycinum list is used | ??2.0 | Irritate stomach | ??0.047±0.016 |
| The Herba polygoni hydropiperis list is used | ??2.0 | Irritate stomach | ??0.046±0.018 |
Compare * p＜0.05, * * * p＜0.001 with the solvent matched group.
6, the inhibitory action of Dichlorodiphenyl Acetate induced mice pain
ICR is 84 of mices, male and female half and half, and body weight 18-22g is divided into 7 groups at random, 12 every group.Experimentize by the acetic acid twisting method.The results are shown in Table 3.The result shows that the mouse writhing reaction that Dichlorodiphenyl Acetate of the present invention causes has certain inhibitory action, and obviously is better than Daphniphyllum calycinum or Herba polygoni hydropiperis list group, and certain dose-effect relationship is arranged, and its analgesic activity intensity is close with bucinnazine.
The inhibitory action of table 3 Dichlorodiphenyl Acetate induced mice of the present invention pain
| Group | Dosage (g/kg) | Route of administration | Number of animals (only) | Writhing response number (inferior) (mean ± standard deviation) |
| The solvent contrast | ??- | Irritate stomach | ??12 | ??18.5±6.1 |
| Group | Dosage (g/kg) | Route of administration | Number of animals (only) | Writhing response number (inferior) (mean ± standard deviation) |
| Bucinnazine | ??0.005 | Intramuscular injection | ??12 | ??4.7±2.5** |
| The present invention | ??0.5 | Irritate stomach | ??12 | ??5.2±3.1** |
| The present invention | ??1.0 | Irritate stomach | ??12 | ??4.3±1.8** |
| The present invention | ??2.0 | Irritate stomach | ??12 | ??3.9±2.0** |
| The Daphniphyllum calycinum list is used | ??2.0 | Irritate stomach | ??12 | ??10.5±3.6* |
| The Herba polygoni hydropiperis list is used | ??2.0 | Irritate stomach | ??12 | ??8.7±2.9* |
Compare * p＜0.05, * * p＜0.01 with the solvent matched group.
The present invention uses the zoopery conclusion of preparation medicine:
In sum, experimentation confirms that the medicine that the present invention uses preparation has many-sided pharmacological action: 1, can obviously suppress rat assist agent arthritis and other experimental inflammation; 2, can obviously suppress mouse skin delayed hypersensitivity and reticuloendothelial system phagocytic function; 3, obvious analgesic activity is arranged.In addition, the pharmacological action of the moist disease of compositions wind resistance that the present invention uses obviously be better than the Daphniphyllum calycinum list with or Herba polygoni hydropiperis list usefulness, show that Daphniphyllum calycinum and Herba polygoni hydropiperis compatibility synergism are very obvious among the present invention.The medicine that above result uses preparation for the present invention is prevented and treated rheumatism clinically provides experimental basis.
Be this routine human research's situation below:
Medicine with the embodiment of the invention 1 preparation: of the present invention group 120 example, male 58 examples, women 62 examples, 30.5 years old mean age, average 8.29 of the course of disease; Radix Tripterygii Wilfordii tablet matched group 120 examples, male 61 examples, women 59 examples, 27.5 years old mean age, average 8.52 of the course of disease.All patients all withdraw other all medicines, of the present invention group of only oral the present invention, every day 3 times, each 4; The only oral Radix Tripterygii Wilfordii tablet of Radix Tripterygii Wilfordii tablet matched group, every day 3 times, each 2; 14 days is a course of treatment.By the listed diagnostic criteria of Ministry of Health of the People's Republic of China's " new drug (Chinese medicine) treatment arthromyodynia clinical research guideline ", include standard in, exclusion standard, therapeutic evaluation standard and statistical standard etc. are implemented at random of the present invention, double blinding, positive drug contrast clinical research.As a result, cure 55 examples for of the present invention group, produce effects 36 examples, 12 examples that take a turn for the better, invalid 17 examples, total effective rate is 85.8%, and any untoward reaction does not take place in the therapeutic process.The Radix Tripterygii Wilfordii tablet matched group is cured 48 examples, produce effects 26 examples, and 18 examples that take a turn for the better, invalid 28 examples, total effective rate is 76.7%; Gastrointestinal reactions such as nauseating and stomachache take place in 12 examples in the therapeutic process, and abnormal liver function appears in 3 examples, and renal dysfunction appears in 5 examples, and electrocardiographic abnormality appears in 2 examples.As seen, the present invention treats traditional Chinese medical science arthromyodynia (being the rheumatism of doctor trained in Western medicine), and not only curative effect is apparently higher than Radix Tripterygii Wilfordii preparation commonly used clinically, and safe, patient is easy to accept.
Embodiment 2
Get Daphniphyllum calycinum 4500g, Herba polygoni hydropiperis 500g adds 4 times of water gagings and soaks after 3 hours, decoct and extract 2 times, the 1st time 2 hours, the 2nd time 1 hour, collecting decoction filters, and filtrate decompression is concentrated into thick paste, dry, be ground into fine powder, add an amount of granule adjuvant lactose commonly used and cyclamate etc., mixing, be distributed into 1000 the bag, use the granule of preparation with the present invention.
Use amount and method: each 4-6 bag, every day 3-4 time, oral.
Embodiment 3
Get Daphniphyllum calycinum 600g, Herba polygoni hydropiperis 5400g adds 6 times of water gagings and soaks after 2 hours, decoct and extract 2 times, the 1st time 2 hours, the 2nd time 1 hour, collecting decoction filters, and filtrate decompression is concentrated into thick paste, dry, be ground into fine powder, mix, splash in the not miscible condensed fluid with drop pill adjuvant gelatin commonly used etc., make 1000 balls, use the drop pill of preparation with the present invention.
Use amount and method: each 6-8 ball, every day 3-4 time, oral.
Embodiment 4
Get Daphniphyllum calycinum 1500g, Herba polygoni hydropiperis 4500g adds 8 times of water gagings and soaks after 3 hours, decoct and extract 3 times, the 1st time 2 hours, the 2nd time 1 hour, the 3rd time 1 hour, collecting decoction filtered, filtrate decompression is concentrated into thick paste, and drying is ground into fine powder, mix with soft capsule adjuvant lecithin commonly used etc., be sealed in the soft capsule material of making by gelatin etc., make 1000, use the soft capsule of preparation with the present invention.
Use amount and method: each 6-8 grain, every day 3-4 time, oral.
Embodiment 5
Get Daphniphyllum calycinum 3000g, Herba polygoni hydropiperis 3000g adds 4 times of water gagings and soaks after 3 hours, decoct and extract 2 times, the 1st time 2 hours, the 2nd time 1 hour, collecting decoction filters, and filtrate decompression is concentrated into thick paste, dry, be ground into fine powder, mix, divide in the capsule of packing into capsule adjuvant lactose commonly used etc., become 1000, use the capsule of preparation with the present invention.
Use amount and method: each 6-8 grain, every day 3-4 time, oral.
Embodiment 6-10 prepares the raw materials of effective components proportioning (unit: g) that adopts
According to clinical experiment, the effective ingredient preferred weight proportioning of using preparation control rheumatism medicine with the present invention is:
Daphniphyllum calycinum 1-6 part Herba polygoni hydropiperis 1-6 part.
The optimum weight proportioning is:
1 part of 2 parts of Herba polygoni hydropiperis of Daphniphyllum calycinum.
Claims (5)
1. Daphniphyllum calycinum and Herba polygoni hydropiperis compositions are as the application of preparation control rheumatism medicine, and it is characterized in that: when preparation prevented and treated the medicine of rheumatism, the effective ingredient of employing was made up of the following weight Chinese medicinal raw materials:
Daphniphyllum calycinum 1-9 part Herba polygoni hydropiperis 1-9 part.
2. Daphniphyllum calycinum according to claim 1 and Herba polygoni hydropiperis compositions are as the application of preparation control rheumatism medicine, and it is characterized in that: the effective ingredient of employing is made up of the following weight Chinese medicinal raw materials:
Daphniphyllum calycinum 1-6 part Herba polygoni hydropiperis 1-6 part.
3. Daphniphyllum calycinum according to claim 1 and Herba polygoni hydropiperis compositions are as the application of preparation control rheumatism medicine, and it is characterized in that: the effective ingredient of employing is made up of the following weight Chinese medicinal raw materials:
1 part of 2 parts of Herba polygoni hydropiperis of Daphniphyllum calycinum.
4. according to the application as preparation control rheumatism medicine of the described Daphniphyllum calycinum of the arbitrary claim of claim 1-3 and Herba polygoni hydropiperis compositions, it is characterized in that: the medicine of making is the Chinese patent medicine of Tabules.
5. according to the application of the described Daphniphyllum calycinum of the arbitrary claim of claim 1-3 and Herba polygoni hydropiperis compositions as preparation control rheumatism medicine, it is characterized in that: the medicine of making is a granule, or capsule, or pill, or drop pill, or the Chinese patent medicine of soft capsule dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810177501A CN101732420A (en) | 2008-11-13 | 2008-11-13 | Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810177501A CN101732420A (en) | 2008-11-13 | 2008-11-13 | Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101732420A true CN101732420A (en) | 2010-06-16 |
Family
ID=42456788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810177501A Pending CN101732420A (en) | 2008-11-13 | 2008-11-13 | Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732420A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239376A (en) * | 2013-05-09 | 2013-08-14 | 洪圣娟 | Red-knees herb no-clean type sterilizing and foot-tendering condensation |
-
2008
- 2008-11-13 CN CN200810177501A patent/CN101732420A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239376A (en) * | 2013-05-09 | 2013-08-14 | 洪圣娟 | Red-knees herb no-clean type sterilizing and foot-tendering condensation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766773B (en) | Chinese medicine prescription for treating talagia | |
| CN102920922B (en) | Bone pain pill | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN102698022B (en) | Externally-used pharmaceutical formulation for nursing or treating haemorrhoids | |
| CN103169928A (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN1931277B (en) | Osteoarthrosis treating Chinese medicine composition and its preparation process | |
| CN100431593C (en) | Chinese medicinal formulation for treating hydrocephalus | |
| CN101040949B (en) | Medicine compound for creating rheumatism and rheumatoid arthritis and the preparing method and application | |
| CN102824576B (en) | Traditional Chinese medicinal composition for treating psoriasis and preparation method thereof | |
| CN101385784B (en) | Application of composition of daphniphyllum calycinum and ciderage for preparing drugs to prevent blockage syndrome | |
| CN101732420A (en) | Application of daphniphyllum calycinum benth and red-knees herb composition in preparing medicament for preventing and treating rheumatic diseases | |
| CN102488781A (en) | Traditional Chinese medicine composition for treating wind-damp-cold arthralgia | |
| CN108686146B (en) | Externally applied plaster for promoting blood circulation to remove blood stasis and preparation method thereof | |
| CN102406870A (en) | Medicament for treating rheumatic arthralgia | |
| CN106237030A (en) | A kind of Chinese medicine composition treating infant eczema and preparation method thereof | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN102430096B (en) | Medicament for treating rheumatic or rheumatoid diseases | |
| CN100398143C (en) | Medicament for treating vitiligo | |
| CN111920883A (en) | External preparation for treating herpes zoster and preparation method thereof | |
| CN101797309A (en) | Traditional Chinese medicine for treating scleriasis and venereal disease | |
| CN104887970A (en) | Acupuncture and moxibustion physiotherapy ointment for external use | |
| CN100571746C (en) | A kind of Traditional Chinese Medicine for external application compositions for the treatment of rheumatic arthritis or vertebral body calcification of posterior longitudinal ligament | |
| CN104474308A (en) | Traditional Chinese medicine composition for treating acute cystitis | |
| CN103768290A (en) | Traditional Chinese medicine composition for treating synovitis and preparation method thereof | |
| CN102872287A (en) | Traditional Chinese medicine composition for treating femoral head necrosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100616 |